Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in December was 12. The number of convertibles remaining during the first tranche for future conversion is 58. Through the conversion, the number of shares and votes increased by 230 769. The terms of the convertibles are published on Episurf Medical AB’s website.
The total number of shares amounts to 31,631,169, of which 5,221,662 are A shares and 26,409,507 are B shares. The total number of votes after the conversions amounts to 42,074,493.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CET on December 28, 2018.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlContact:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">Change in number of shares and votes in Episurf Medical</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in December was 12. The number of convertibles remaining during the first tranche for future conversion is 58. Through the conversion, the number of shares and votes increased by 230 769. The terms of the convertibles are published on Episurf Medical AB's website.
The total number of shares amounts to 31,631,169, of which 5,221,662 are A shares and 26,409,507 are B shares. The total number of votes after the conversions amounts to 42,074,493.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CET on December 28, 2018.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in December was 12. The number of convertibles remaining during the first tranche for future conversion is 58. Through the conversion, the number of shares and votes increased by 230 769. The terms of the convertibles are published on Episurf Medical AB's website.</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">The total number of shares amounts to 31,631,169, of which 5,221,662 are A shares and 26,409,507 are B shares. The total number of votes after the conversions amounts to 42,074,493.</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Veronica Wallin, CFO, Episurf Medical<br /></span><span style="font-size: 10pt;">Tel:</span><span style="font-size: 10pt;">+46 (0) 700 37 48 95<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">veronica.wallin@episurf.com</a></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><em><span style="font-size: 10pt;">This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CET on December 28, 2018.</span></em></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S8
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 075
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2703578/969118.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Change in number of shares and votes in Episurf Medical
[Description:protected] => Change in number of shares and votes in Episurf Medical
[CreateDate:protected] => 2018-12-28T10:00:06Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3165723
[EncryptedId:protected] => 48E21C3AA35E27E3
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2018-12-28T10:00:00Z
[LastChangeDate:protected] => 2018-12-28T10:00:06Z
[Title:protected] => Change in number of shares and votes in Episurf Medical
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/change-in-number-of-shares-and-votes-in-episurf-medical,c2703578
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)